Global Sjogren's Syndrome Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Sjogren's Syndrome also known as show grins is a type of autoimmune disease that affects different parts of the body that are responsible for producing fluids, like tears and spit (saliva). It mainly affects people aged between 40 to 60 years. Sjogren's Syndrome symptoms include dry eyes & dry mouth. The increasing number of patients with Sjogren's Syndrome and growing awareness towards Sjogren's Syndrome as well as strategic initiatives from leading market players are key factors accelerating the market growth.
According to Reston, Virginia, USA based Sjogren's Foundation estimates - as of 2020, autoimmune diseases affect 5 to 8% of US residents. In addition, approximately four million American citizens are affected by Sjogren's Syndrome, with more than 2.5 million patients are steel undiagnosed. Moreover, as per The National Institutes of Health (NIH) estimates - approximately 23.5 million Americans are affected by autoimmune diseases. Also, rising growth of pharmaceuticals sector in emerging markets and growing number of R&D activities in medical sector would create lucrative growth prospectus for the market over the forecast period. However, the high treatment cost associated with Sjogren's Syndrome impedes the market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Sjogren's Syndrome Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factor such as presence of leading market players and availability of robust healthcare infrastructure in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising prevalence of Sjogren's syndrome as well as growing healthcare infrastructure in the region.
Major market players included in this report are:
ADVANZ PHARMA Corp. Ltd
Bristol-Myers Squibb Co
Daiichi Sankyo Co. Ltd
Hikma Pharmaceuticals Plc
Johnson & Johnson
Sun Pharmaceutical Industries Ltd.
Recent Developments in the Market:
In September 2022, Dublin Ireland based Horizon Therapeutics plc Announced Phase 2 trial of its new formulation Dazodalibep for the Treatment of Sjogren's Syndrome. In addition, as per the score defined by the European Alliance of Associations for Rheumatology (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI), the drug has met the primary endpoint in patients with moderate-to-high systemic disease activity.
In September 2022, Switzerland based pharma major Novartis announced completion of Phase II immune disorder trial of its new formulation named remibrutinib (LOU-064).
Global Sjogren's Syndrome Market Report Scope:
Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Application, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
Primary Sjogren's Syndrome
Secondary Sjogren's Syndrome)
By Distribution Channel
Rest of the World